Arcutis Biotherapeutics

Update in progress

ARQT (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on dermatology therapies. Its lead product, ZORYVE, is a topical roflumilast cream approved for plaque psoriasis and atopic dermatitis, with ZORYVE foam under development for seborrheic dermatitis and scalp and body psoriasis. ARQ-234 is a fusion protein acting as a checkpoint agonist of the CD200 receptor. The company, renamed in 2019, was founded in 2016 and is headquartered in Westlake Village, California.

Company score

Sentiment: 0.50; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.44; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.14; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.32; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationUnited States
CEOMr. Todd Franklin Watanabe M.A.
Founded2016
Employees354
Websitewww.arcutis.com

Identifiers

ISINUS03969K1088
FIGIBBG00QN8K4M4
CUSIP03969K108
CIK0001787306